Clinical Trial Update: Ticagrelor China Pharmacokinetic/Pharmacodynamic Study [Phase 4]

View source ↗

Summary

Phase 4 pharmacokinetic/pharmacodynamic study of ticagrelor conducted in China has completed, with results posted on 2016-05-11.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease
• Stable Coronary Artery Disease

Drugs mentioned

• TICAGRELOR (ticagrelor)

Snippet

Sponsor: AstraZeneca | Conditions: Stable Coronary Heart Disease (CHD) | Phase 4 | Status: COMPLETED | Results posted: 2016-05-11